The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-03 and is reviewed periodically as new material appears.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
==== Pancreatic beta cells ==== People with Type 1 diabetes lose the function of insulin-producing beta cells within the pancreas. In a 2007 publication of experiments, scientists have been able to coax embryonic stem cells to turn into beta cells in the lab. In theory, if the beta cell is transplanted successfully, they will be able to replace malfunctioning ones in a diabetic patient. There are adverse effects of high glucose concentrations on stem cell therapy, however.
Globally, infants are a group that is especially vulnerable to foodborne disease. The World Health Organization has issued recommendations for the preparation, use and storage of prepared formulas. Breastfeeding remains the best preventive measure for protection from foodborne infections in infants.
In 2008, Freeman was cast in the action-thriller Wanted, a loose adaptation of the comic book miniseries by Mark Millar and J. G. Jones. The plot revolves around Wesley Gibson (James McAvoy), a frustrated account manager who discovers that he is the son of a professional assassin and decides to join the Fraternity, a secret society of which Sloan (Freeman) is the leader. Principal photography took place in Chicago; co-star rapper Common remarked on the set atmosphere: "Freeman is a cool guy. He'd be walking around joking and singing and just dancing. You know, artists are free and I just felt the freedom in him." The film received generally favorable reviews; Peter Howell of Toronto Star thought it was original and one of Freeman's bolder performances to date. Freeman narrated The Love Guru (2008), before appearing in The Dark Knight (2008), the second installment of Christopher Nolan's Dark Knight Trilogy, in which he reprised his role as Lucius Fox. Freeman returned to Broadway in 2008 after an eighteen-year absence to co-star with Frances McDormand and Peter Gallagher in Clifford Odets' play, The Country Girl, directed by Mike Nichols. Freeman continued to accept roles in a diverse range of genres. In 2009, Freeman starred opposite Antonio Banderas in the heist movie Thick as Thieves. Next, he collaborated with Christopher Walken and William H. Macy for the comedy The Maiden Heist. For some time, Freeman expressed a desire to do a film based on Nelson Mandela.
== Metabolism == The bacteria rely on the enzyme glycerol-3-phosphate dehydrogenase (GPDH). GPDH is an alternative when managing electrons that are produced during metabolism. In the absence of the electron transport chain, T. pallidum uses GPDH to recycle the NAD+ by oxidizing glycerol-3-phosphate to dihydroxyacetone phosphate and make NAD+ to keep glycolysis and other redox-dependent energy reactions. By doing this, it helps balance the ATP yield without weighing down the protein's limited supply for essential tasks. T. pallidum uses an enzyme called pyrophosphate-dependent phosphofructokinase rather than ATP as a way to save energy and optimize its limited resources. T. pallidum manages without a complete tricarboxylic acid cycle and oxidative phosphorylation by using different efficient strategies including redox balancing and substrate-level to survive the nutrient-limited host environment. T. pallidum lacks enzyme orthologs for superoxide dismutase, however it does possess a superoxide reductase, maintaining the ability to reduce reactive oxygen species. In addition, T. pallidum encodes an alkyl hydroperoxide reductase C, which allows for the reduction of hydrogen peroxide to water and alcohols. This enzyme relies on TP0919, a protein present in the cytoplasm of T. pallidum. T.pallidum primarily relies on glucose as its primary carbon source through glycolysis, but one study has proposed the bacterium uses an acetogenic-energy conservation pathway as a way to catabolize D-lactate as an alternative carbon source.
Sources: en.wikipedia.org
== See also == 3-Methylbutyrfentanyl 3-Methylfentanyl 4-Fluorobutyrfentanyl 4-Fluoroisobutyrfentanyl α-Methylfentanyl Acetylfentanyl Butyrfentanyl Furanylfentanyl Orthofluorofentanyl List of fentanyl analogues
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved median overall survival by 5.8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration (FDA) approved marketing on 22 February 2013. Trastuzumab emtansine was developed by Genentech, and is manufactured by Lonza.
== Veterinary uses == Thiamazole is commonly used in cats to treat hyperthyroidism. Despite 20% of cats treated with thiamazole testing positive for antinuclear antibody lupus erythematosus and immune-mediated haemolytic anemia, neither condition is associated with thiamazole in cats. Hepatic toxicity also occurs in a small but notable amount of cats treated with thiamazole. In July 2024, the US Food and Drug Administration (FDA) approved Felanorm, the first generic methimazole oral solution for the treatment of hyperthyroidism in cats. Felanorm contains the same active ingredient (methimazole) as the approved brand name drug product, Felimazole Coated Tablets, which were first approved in May 2009. In addition, the FDA determined that Felanorm contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. Felanorm is sponsored by Norbrook Laboratories based in the United Kingdom.
Sources: en.wikipedia.org
== Research == Flupirtine has been noted for its neuroprotective properties, and has been investigated for possible use in Creutzfeldt–Jakob disease, Alzheimer's disease, and multiple sclerosis. It has also been proposed as a possible treatment for Batten disease. Flupirtine underwent a clinical trial as a treatment for multiple sclerosis and fibromyalgia. Flupirtine showed promise for fibromyalgia due to its different action than the three approved by U.S. FDA drugs: pregabalin, milnacipran, and duloxetine. Additionally, there are case reports regarding flupirtine as a treatment for fibromyalgia. Adeona Pharmaceuticals (now called Synthetic Biologics) sub-licensed its patents for using flupirtine for fibromyalgia to Meda AB in May 2010.
== See also == List of University of California, Berkeley faculty List of University of California, Berkeley alumni in business and entrepreneurship List of University of California, Berkeley alumni in science and technology
This militaristic sub-team of the X-Men, which initially also included X-23 (Wolverine's daughter), featured in its own ongoing series, written by Craig Kyle and Christopher Yost, from 2008 to 2010. In 2008, Brian K. Vaughan and Eduardo Risso collaborated to produce the Logan miniseries (April–June), which recounted one of Logan's adventures in Japan at the conclusion of World War II.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.